WO2022175434A2 - Composition emulsion et ses utilisations dans la prevention et/ou le traitement des dommages cutanes causes par les rayonnements - Google Patents
Composition emulsion et ses utilisations dans la prevention et/ou le traitement des dommages cutanes causes par les rayonnements Download PDFInfo
- Publication number
- WO2022175434A2 WO2022175434A2 PCT/EP2022/054044 EP2022054044W WO2022175434A2 WO 2022175434 A2 WO2022175434 A2 WO 2022175434A2 EP 2022054044 W EP2022054044 W EP 2022054044W WO 2022175434 A2 WO2022175434 A2 WO 2022175434A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- composition according
- combination
- composition
- brimonidine
- skin
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 221
- 239000000839 emulsion Substances 0.000 title claims abstract description 52
- 238000011282 treatment Methods 0.000 title claims description 28
- 230000005855 radiation Effects 0.000 title claims description 26
- 230000002265 prevention Effects 0.000 title claims description 9
- 230000037380 skin damage Effects 0.000 title description 4
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims abstract description 121
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerol Natural products OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims abstract description 60
- XYLJNLCSTIOKRM-UHFFFAOYSA-N Alphagan Chemical compound C1=CC2=NC=CN=C2C(Br)=C1NC1=NCCN1 XYLJNLCSTIOKRM-UHFFFAOYSA-N 0.000 claims abstract description 51
- 229960003679 brimonidine Drugs 0.000 claims abstract description 50
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 47
- 239000002904 solvent Substances 0.000 claims abstract description 33
- 235000011187 glycerol Nutrition 0.000 claims abstract description 29
- 239000004973 liquid crystal related substance Substances 0.000 claims abstract description 28
- 150000003839 salts Chemical class 0.000 claims abstract description 25
- 229920001223 polyethylene glycol Polymers 0.000 claims abstract description 22
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims abstract description 22
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims abstract description 22
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims abstract description 22
- ALSTYHKOOCGGFT-KTKRTIGZSA-N (9Z)-octadecen-1-ol Chemical compound CCCCCCCC\C=C/CCCCCCCCO ALSTYHKOOCGGFT-KTKRTIGZSA-N 0.000 claims abstract description 17
- 239000002202 Polyethylene glycol Substances 0.000 claims abstract description 16
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 claims abstract description 15
- 229920001577 copolymer Polymers 0.000 claims abstract description 13
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 claims abstract description 12
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 12
- 239000003995 emulsifying agent Substances 0.000 claims abstract description 9
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 claims abstract description 6
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 claims abstract description 6
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 claims abstract description 6
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 claims abstract description 6
- 239000005642 Oleic acid Substances 0.000 claims abstract description 6
- 229920001214 Polysorbate 60 Polymers 0.000 claims abstract description 6
- 229940075507 glyceryl monostearate Drugs 0.000 claims abstract description 6
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 claims abstract description 6
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 claims abstract description 6
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims abstract description 6
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 claims abstract description 6
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical group CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims abstract description 5
- 229940082500 cetostearyl alcohol Drugs 0.000 claims abstract description 5
- OULAJFUGPPVRBK-UHFFFAOYSA-N tetratriacontyl alcohol Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCO OULAJFUGPPVRBK-UHFFFAOYSA-N 0.000 claims abstract description 5
- 230000000699 topical effect Effects 0.000 claims description 27
- IWEGDQUCWQFKHS-UHFFFAOYSA-N 1-(1,3-dioxolan-2-ylmethyl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrazole Chemical compound O1C(C)(C)C(C)(C)OB1C1=CN(CC2OCCO2)N=C1 IWEGDQUCWQFKHS-UHFFFAOYSA-N 0.000 claims description 20
- 229960001724 brimonidine tartrate Drugs 0.000 claims description 20
- 238000001959 radiotherapy Methods 0.000 claims description 16
- ALSTYHKOOCGGFT-UHFFFAOYSA-N cis-oleyl alcohol Natural products CCCCCCCCC=CCCCCCCCCO ALSTYHKOOCGGFT-UHFFFAOYSA-N 0.000 claims description 12
- 239000000230 xanthan gum Substances 0.000 claims description 11
- 235000010493 xanthan gum Nutrition 0.000 claims description 11
- 229920001285 xanthan gum Polymers 0.000 claims description 11
- 229940082509 xanthan gum Drugs 0.000 claims description 11
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 claims description 10
- -1 triglyceride ester Chemical class 0.000 claims description 10
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 claims description 9
- 239000003963 antioxidant agent Substances 0.000 claims description 8
- 235000006708 antioxidants Nutrition 0.000 claims description 8
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims description 7
- 235000019282 butylated hydroxyanisole Nutrition 0.000 claims description 7
- QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 claims description 6
- WRMNZCZEMHIOCP-UHFFFAOYSA-N 2-phenylethanol Chemical compound OCCC1=CC=CC=C1 WRMNZCZEMHIOCP-UHFFFAOYSA-N 0.000 claims description 6
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 6
- 229960005323 phenoxyethanol Drugs 0.000 claims description 6
- 239000004255 Butylated hydroxyanisole Substances 0.000 claims description 5
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 claims description 5
- 235000013162 Cocos nucifera Nutrition 0.000 claims description 5
- 244000060011 Cocos nucifera Species 0.000 claims description 5
- 235000001815 DL-alpha-tocopherol Nutrition 0.000 claims description 5
- 239000011627 DL-alpha-tocopherol Substances 0.000 claims description 5
- 230000003078 antioxidant effect Effects 0.000 claims description 5
- 229940043253 butylated hydroxyanisole Drugs 0.000 claims description 5
- CZBZUDVBLSSABA-UHFFFAOYSA-N butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 claims description 5
- 229960000541 cetyl alcohol Drugs 0.000 claims description 5
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 5
- 239000000194 fatty acid Substances 0.000 claims description 5
- 229930195729 fatty acid Natural products 0.000 claims description 5
- 150000004665 fatty acids Chemical class 0.000 claims description 5
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 claims description 5
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 claims description 5
- 229960002216 methylparaben Drugs 0.000 claims description 5
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 claims description 5
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 claims description 5
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 claims description 4
- 229920001451 polypropylene glycol Polymers 0.000 claims description 4
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 claims description 4
- 229920006395 saturated elastomer Polymers 0.000 claims description 4
- HBXWUCXDUUJDRB-UHFFFAOYSA-N 1-octadecoxyoctadecane Chemical compound CCCCCCCCCCCCCCCCCCOCCCCCCCCCCCCCCCCCC HBXWUCXDUUJDRB-UHFFFAOYSA-N 0.000 claims description 3
- FJKROLUGYXJWQN-UHFFFAOYSA-N 4-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 claims description 3
- 201000004624 Dermatitis Diseases 0.000 claims description 3
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 claims description 3
- 229940072107 ascorbate Drugs 0.000 claims description 3
- 235000010323 ascorbic acid Nutrition 0.000 claims description 3
- 239000011668 ascorbic acid Substances 0.000 claims description 3
- 229940067107 phenylethyl alcohol Drugs 0.000 claims description 3
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 claims description 3
- 235000010234 sodium benzoate Nutrition 0.000 claims description 3
- 239000004299 sodium benzoate Substances 0.000 claims description 3
- 235000013311 vegetables Nutrition 0.000 claims description 3
- 229940123457 Free radical scavenger Drugs 0.000 claims description 2
- 108010024636 Glutathione Proteins 0.000 claims description 2
- CMHMMKSPYOOVGI-UHFFFAOYSA-N Isopropylparaben Chemical compound CC(C)OC(=O)C1=CC=C(O)C=C1 CMHMMKSPYOOVGI-UHFFFAOYSA-N 0.000 claims description 2
- NBBJYMSMWIIQGU-UHFFFAOYSA-N Propionic aldehyde Chemical compound CCC=O NBBJYMSMWIIQGU-UHFFFAOYSA-N 0.000 claims description 2
- 229960003180 glutathione Drugs 0.000 claims description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 claims description 2
- 229940113094 isopropylparaben Drugs 0.000 claims description 2
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 claims description 2
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 claims description 2
- 229960003415 propylparaben Drugs 0.000 claims description 2
- 239000002516 radical scavenger Substances 0.000 claims description 2
- 229960003885 sodium benzoate Drugs 0.000 claims description 2
- 239000005526 vasoconstrictor agent Substances 0.000 abstract description 14
- 238000011200 topical administration Methods 0.000 abstract description 8
- 229940055577 oleyl alcohol Drugs 0.000 abstract description 5
- XMLQWXUVTXCDDL-UHFFFAOYSA-N oleyl alcohol Natural products CCCCCCC=CCCCCCCCCCCO XMLQWXUVTXCDDL-UHFFFAOYSA-N 0.000 abstract description 5
- 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 abstract description 2
- 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 abstract description 2
- 229940113124 polysorbate 60 Drugs 0.000 abstract description 2
- 210000003491 skin Anatomy 0.000 description 71
- 230000002087 whitening effect Effects 0.000 description 35
- 239000012071 phase Substances 0.000 description 33
- 238000009472 formulation Methods 0.000 description 32
- 230000000694 effects Effects 0.000 description 30
- 206010047139 Vasoconstriction Diseases 0.000 description 24
- 230000025033 vasoconstriction Effects 0.000 description 24
- 239000004480 active ingredient Substances 0.000 description 23
- 238000000034 method Methods 0.000 description 22
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 20
- 239000007764 o/w emulsion Substances 0.000 description 20
- 210000000434 stratum corneum Anatomy 0.000 description 20
- 230000008569 process Effects 0.000 description 17
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 description 15
- QZHBYNSSDLTCRG-WUUYCOTASA-N brimonidine tartrate Chemical compound [H+].[H+].[O-]C(=O)[C@@H](O)[C@H](O)C([O-])=O.C1=CC2=NC=CN=C2C(Br)=C1NC1=NCCN1 QZHBYNSSDLTCRG-WUUYCOTASA-N 0.000 description 14
- 239000000499 gel Substances 0.000 description 14
- 208000006934 radiodermatitis Diseases 0.000 description 14
- 206010015150 Erythema Diseases 0.000 description 13
- 229940032979 mirvaso Drugs 0.000 description 13
- 230000035515 penetration Effects 0.000 description 13
- 231100000321 erythema Toxicity 0.000 description 12
- 235000013772 propylene glycol Nutrition 0.000 description 11
- 229960004063 propylene glycol Drugs 0.000 description 11
- 239000000243 solution Substances 0.000 description 11
- 238000011156 evaluation Methods 0.000 description 10
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 9
- 238000001727 in vivo Methods 0.000 description 9
- 239000007762 w/o emulsion Substances 0.000 description 9
- 206010028980 Neoplasm Diseases 0.000 description 8
- 230000008901 benefit Effects 0.000 description 8
- 150000001875 compounds Chemical class 0.000 description 8
- 239000006071 cream Substances 0.000 description 8
- 238000004945 emulsification Methods 0.000 description 8
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 7
- 229920003083 Kollidon® VA64 Polymers 0.000 description 7
- 230000009471 action Effects 0.000 description 7
- 201000011510 cancer Diseases 0.000 description 7
- 238000001816 cooling Methods 0.000 description 7
- 238000002156 mixing Methods 0.000 description 7
- 229960002748 norepinephrine Drugs 0.000 description 7
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 7
- 230000002035 prolonged effect Effects 0.000 description 7
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 6
- 239000013543 active substance Substances 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- CBGUOGMQLZIXBE-XGQKBEPLSA-N clobetasol propionate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CCl)(OC(=O)CC)[C@@]1(C)C[C@@H]2O CBGUOGMQLZIXBE-XGQKBEPLSA-N 0.000 description 6
- 230000002500 effect on skin Effects 0.000 description 6
- 238000005259 measurement Methods 0.000 description 6
- 201000004700 rosacea Diseases 0.000 description 6
- 238000003756 stirring Methods 0.000 description 6
- 238000005303 weighing Methods 0.000 description 6
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 6
- 230000004888 barrier function Effects 0.000 description 5
- 229960004703 clobetasol propionate Drugs 0.000 description 5
- 210000002615 epidermis Anatomy 0.000 description 5
- 230000001976 improved effect Effects 0.000 description 5
- 230000001965 increasing effect Effects 0.000 description 5
- 239000002245 particle Substances 0.000 description 5
- 239000000546 pharmaceutical excipient Substances 0.000 description 5
- 230000009467 reduction Effects 0.000 description 5
- 241001303601 Rosacea Species 0.000 description 4
- 238000013019 agitation Methods 0.000 description 4
- 210000000038 chest Anatomy 0.000 description 4
- 239000003246 corticosteroid Substances 0.000 description 4
- 229960001334 corticosteroids Drugs 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- 210000004207 dermis Anatomy 0.000 description 4
- 238000009826 distribution Methods 0.000 description 4
- 238000010438 heat treatment Methods 0.000 description 4
- 238000000265 homogenisation Methods 0.000 description 4
- 238000010348 incorporation Methods 0.000 description 4
- 150000002632 lipids Chemical class 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 239000008194 pharmaceutical composition Substances 0.000 description 4
- 229920000642 polymer Polymers 0.000 description 4
- 230000003381 solubilizing effect Effects 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 239000012049 topical pharmaceutical composition Substances 0.000 description 4
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 230000001154 acute effect Effects 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 230000015556 catabolic process Effects 0.000 description 3
- 239000007957 coemulsifier Substances 0.000 description 3
- 230000000295 complement effect Effects 0.000 description 3
- 238000006731 degradation reaction Methods 0.000 description 3
- XXJWXESWEXIICW-UHFFFAOYSA-N diethylene glycol monoethyl ether Chemical compound CCOCCOCCO XXJWXESWEXIICW-UHFFFAOYSA-N 0.000 description 3
- 150000002433 hydrophilic molecules Chemical class 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 238000001556 precipitation Methods 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 238000005063 solubilization Methods 0.000 description 3
- 230000007928 solubilization Effects 0.000 description 3
- 229940012831 stearyl alcohol Drugs 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 239000004408 titanium dioxide Substances 0.000 description 3
- DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical compound C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 description 2
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- 229920002556 Polyethylene Glycol 300 Polymers 0.000 description 2
- 206010042496 Sunburn Diseases 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000001800 adrenalinergic effect Effects 0.000 description 2
- 239000000384 adrenergic alpha-2 receptor agonist Substances 0.000 description 2
- 229940087168 alpha tocopherol Drugs 0.000 description 2
- 239000008346 aqueous phase Substances 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 230000004087 circulation Effects 0.000 description 2
- 230000008705 cutaneous vasoconstriction Effects 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000001815 facial effect Effects 0.000 description 2
- 230000002349 favourable effect Effects 0.000 description 2
- 150000002334 glycols Chemical class 0.000 description 2
- 239000003906 humectant Substances 0.000 description 2
- 230000036571 hydration Effects 0.000 description 2
- 238000006703 hydration reaction Methods 0.000 description 2
- 230000005865 ionizing radiation Effects 0.000 description 2
- 239000002085 irritant Substances 0.000 description 2
- 230000007794 irritation Effects 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 150000002634 lipophilic molecules Chemical class 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000005457 optimization Methods 0.000 description 2
- WYWIFABBXFUGLM-UHFFFAOYSA-N oxymetazoline Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C)=C1CC1=NCCN1 WYWIFABBXFUGLM-UHFFFAOYSA-N 0.000 description 2
- 230000037368 penetrate the skin Effects 0.000 description 2
- 230000002688 persistence Effects 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 239000002798 polar solvent Substances 0.000 description 2
- 229920000191 poly(N-vinyl pyrrolidone) Polymers 0.000 description 2
- 229940096956 ppg-11 stearyl ether Drugs 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000002335 preservative effect Effects 0.000 description 2
- 239000012047 saturated solution Substances 0.000 description 2
- 210000004761 scalp Anatomy 0.000 description 2
- 239000013049 sediment Substances 0.000 description 2
- 230000001953 sensory effect Effects 0.000 description 2
- 230000008591 skin barrier function Effects 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 229940095064 tartrate Drugs 0.000 description 2
- 229960000984 tocofersolan Drugs 0.000 description 2
- 235000010384 tocopherol Nutrition 0.000 description 2
- 229930003799 tocopherol Natural products 0.000 description 2
- 239000011732 tocopherol Substances 0.000 description 2
- 229960001295 tocopherol Drugs 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 238000009281 ultraviolet germicidal irradiation Methods 0.000 description 2
- 210000005166 vasculature Anatomy 0.000 description 2
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 2
- 229920002554 vinyl polymer Polymers 0.000 description 2
- 230000000007 visual effect Effects 0.000 description 2
- 239000002076 α-tocopherol Substances 0.000 description 2
- 235000004835 α-tocopherol Nutrition 0.000 description 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical class OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 1
- 229930182837 (R)-adrenaline Natural products 0.000 description 1
- HNSDLXPSAYFUHK-UHFFFAOYSA-N 1,4-bis(2-ethylhexyl) sulfosuccinate Chemical compound CCCCC(CC)COC(=O)CC(S(O)(=O)=O)C(=O)OCC(CC)CCCC HNSDLXPSAYFUHK-UHFFFAOYSA-N 0.000 description 1
- WXTMDXOMEHJXQO-UHFFFAOYSA-N 2,5-dihydroxybenzoic acid Chemical compound OC(=O)C1=CC(O)=CC=C1O WXTMDXOMEHJXQO-UHFFFAOYSA-N 0.000 description 1
- KWVPFECTOKLOBL-KTKRTIGZSA-N 2-[(z)-octadec-9-enoxy]ethanol Chemical compound CCCCCCCC\C=C/CCCCCCCCOCCO KWVPFECTOKLOBL-KTKRTIGZSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-M 3-carboxy-2,3-dihydroxypropanoate Chemical compound OC(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-M 0.000 description 1
- FQTFHMSZCSUVEU-QRPNPIFTSA-N 4-[(1r)-2-amino-1-hydroxyethyl]benzene-1,2-diol;hydrochloride Chemical compound Cl.NC[C@H](O)C1=CC=C(O)C(O)=C1 FQTFHMSZCSUVEU-QRPNPIFTSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 206010006784 Burning sensation Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- QCZAWDGAVJMPTA-RNFRBKRXSA-N ClC1=CC=CC(=N1)C1=NC(=NC(=N1)N[C@@H](C(F)(F)F)C)N[C@@H](C(F)(F)F)C Chemical compound ClC1=CC=CC(=N1)C1=NC(=NC(=N1)N[C@@H](C(F)(F)F)C)N[C@@H](C(F)(F)F)C QCZAWDGAVJMPTA-RNFRBKRXSA-N 0.000 description 1
- DSLZVSRJTYRBFB-LLEIAEIESA-N D-glucaric acid Chemical compound OC(=O)[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O DSLZVSRJTYRBFB-LLEIAEIESA-N 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
- AEMOLEFTQBMNLQ-AQKNRBDQSA-N D-glucopyranuronic acid Chemical compound OC1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-AQKNRBDQSA-N 0.000 description 1
- 239000004230 Fast Yellow AB Substances 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 206010033546 Pallor Diseases 0.000 description 1
- 229920000604 Polyethylene Glycol 200 Polymers 0.000 description 1
- 229920002582 Polyethylene Glycol 600 Polymers 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 230000037374 absorbed through the skin Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- LPQOADBMXVRBNX-UHFFFAOYSA-N ac1ldcw0 Chemical compound Cl.C1CN(C)CCN1C1=C(F)C=C2C(=O)C(C(O)=O)=CN3CCSC1=C32 LPQOADBMXVRBNX-UHFFFAOYSA-N 0.000 description 1
- 229940022663 acetate Drugs 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 208000030961 allergic reaction Diseases 0.000 description 1
- 102000030619 alpha-1 Adrenergic Receptor Human genes 0.000 description 1
- 108020004102 alpha-1 Adrenergic Receptor Proteins 0.000 description 1
- 102000030484 alpha-2 Adrenergic Receptor Human genes 0.000 description 1
- 108020004101 alpha-2 Adrenergic Receptor Proteins 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 239000012080 ambient air Substances 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 238000011394 anticancer treatment Methods 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 210000002565 arteriole Anatomy 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 229940125717 barbiturate Drugs 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- 229940077388 benzenesulfonate Drugs 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 229960001102 betamethasone dipropionate Drugs 0.000 description 1
- CIWBQSYVNNPZIQ-XYWKZLDCSA-N betamethasone dipropionate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)COC(=O)CC)(OC(=O)CC)[C@@]1(C)C[C@@H]2O CIWBQSYVNNPZIQ-XYWKZLDCSA-N 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 238000004061 bleaching Methods 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 229960001631 carbomer Drugs 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 229940001468 citrate Drugs 0.000 description 1
- 238000005352 clarification Methods 0.000 description 1
- 229960002842 clobetasol Drugs 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 238000007596 consolidation process Methods 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- STORWMDPIHOSMF-UHFFFAOYSA-N decanoic acid;octanoic acid;propane-1,2,3-triol Chemical compound OCC(O)CO.CCCCCCCC(O)=O.CCCCCCCCCC(O)=O STORWMDPIHOSMF-UHFFFAOYSA-N 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 230000036576 dermal application Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 230000001687 destabilization Effects 0.000 description 1
- 230000000368 destabilizing effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical class OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 229940008099 dimethicone Drugs 0.000 description 1
- 239000004205 dimethyl polysiloxane Substances 0.000 description 1
- 235000013870 dimethyl polysiloxane Nutrition 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 239000003974 emollient agent Substances 0.000 description 1
- 229960005139 epinephrine Drugs 0.000 description 1
- 238000011067 equilibration Methods 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 150000002191 fatty alcohols Chemical class 0.000 description 1
- 229940050411 fumarate Drugs 0.000 description 1
- 239000003349 gelling agent Substances 0.000 description 1
- 229940050410 gluconate Drugs 0.000 description 1
- 229940097042 glucuronate Drugs 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 229960005150 glycerol Drugs 0.000 description 1
- 125000003976 glyceryl group Chemical group [H]C([*])([H])C(O[H])([H])C(O[H])([H])[H] 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 201000006747 infectious mononucleosis Diseases 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 231100000021 irritant Toxicity 0.000 description 1
- TWBYWOBDOCUKOW-UHFFFAOYSA-M isonicotinate Chemical compound [O-]C(=O)C1=CC=NC=C1 TWBYWOBDOCUKOW-UHFFFAOYSA-M 0.000 description 1
- 229940001447 lactate Drugs 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 239000003589 local anesthetic agent Substances 0.000 description 1
- 229960005015 local anesthetics Drugs 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 229940126601 medicinal product Drugs 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 230000002906 microbiologic effect Effects 0.000 description 1
- NJTGANWAUPEOAX-UHFFFAOYSA-N molport-023-220-454 Chemical compound OCC(O)CO.OCC(O)CO NJTGANWAUPEOAX-UHFFFAOYSA-N 0.000 description 1
- 231100000344 non-irritating Toxicity 0.000 description 1
- 229940095127 oleth-20 Drugs 0.000 description 1
- 229940054534 ophthalmic solution Drugs 0.000 description 1
- 239000002997 ophthalmic solution Substances 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 229960001528 oxymetazoline Drugs 0.000 description 1
- 208000035824 paresthesia Diseases 0.000 description 1
- 238000005192 partition Methods 0.000 description 1
- 229940119519 peg-32 stearate Drugs 0.000 description 1
- 229940119517 peg-6 stearate Drugs 0.000 description 1
- 239000003961 penetration enhancing agent Substances 0.000 description 1
- JLFNLZLINWHATN-UHFFFAOYSA-N pentaethylene glycol Chemical compound OCCOCCOCCOCCOCCO JLFNLZLINWHATN-UHFFFAOYSA-N 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 238000005191 phase separation Methods 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 239000003642 reactive oxygen metabolite Substances 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000008261 resistance mechanism Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 229960001860 salicylate Drugs 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 230000037394 skin elasticity Effects 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 229940083608 sodium hydroxide Drugs 0.000 description 1
- 239000011877 solvent mixture Substances 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000002636 symptomatic treatment Methods 0.000 description 1
- 231100000057 systemic toxicity Toxicity 0.000 description 1
- 229960005196 titanium dioxide Drugs 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 239000003860 topical agent Substances 0.000 description 1
- 229940025703 topical product Drugs 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 230000002476 tumorcidal effect Effects 0.000 description 1
- 238000000825 ultraviolet detection Methods 0.000 description 1
- 230000024883 vasodilation Effects 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 230000036642 wellbeing Effects 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1274—Non-vesicle bilayer structures, e.g. liquid crystals, tubules, cubic phases, cochleates; Sponge phases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Definitions
- the invention relates to the field of pharmaceutical compositions in a form suitable for topical administration. It relates more particularly to a pharmaceutical composition comprising a vasoconstrictor such as brimonidine or its salts, as well as such a composition for its use as a medicine, more particularly in the prevention and/or treatment of skin damage caused by radiation .
- a vasoconstrictor such as brimonidine or its salts
- UV ultraviolet
- UVA ultraviolet
- UVB ultraviolet
- IR infrared radiation
- ionizing radiation such as X-rays and alpha
- befa ionizing radiation
- gamma radiation even radiation composed of protons.
- One of the first tissue effects of radiation exposure is ⁇ erythema, an inflammatory response causing vasodilation of blood vessels and reddening of the skin. This ⁇ e reaction is ⁇ visible approximately 6 to 8 hours after UV exposure and ⁇ disappears after 36 to 48 hours.
- Dermal application of a highly selective alpha2-adrenergic receptor agonist to the face is known to reduce erythema through direct cutaneous vasoconstriction.
- the main characteristic of cutaneous vasoconstriction is ⁇ pallor; by reducing the diameter of the arterioles and small vessels of the dermis, this causes an immediate reduction in blood flow, producing in particular a reduction in the color of the skin.
- MIRVASO® gel (0.5% w/w brimonidine ⁇ ar ⁇ ra ⁇ e) is ⁇ indicated for the symptomatic treatment of facial erythema associated with rosacea in adults.
- Brimonidine is best known as a highly selective alpha2-adrenergic receptor agonist. Brimonidine is ⁇ 1000 times more selective for alpha2-adrenergic receptors than for alpha 1-adrenergic receptors.
- Brimonidine has been shown to be useful in the treatment of erythema caused by acne rosacea, and has been proposed for other skin disorders, see for example patent application US10/853,585, application by patent US10/626037 and patent application US12/193098.
- Brimonidine ( ⁇ ar ⁇ ra ⁇ e) exhibits appropriate chemical stability for topical administration and a solubility profile that offers different formulation options.
- patent document WO2015013709 describes the reduction and/or inhibition of skin hyperplasia caused by radiation by using brimonidine ⁇ ar ⁇ ra ⁇ e, at a concentration of 0.01 -5% in weight, preferably 0.1-2% by weight, by topical administration, for example in the form of an emulsion. It discloses, for example, a composition comprising an alcoholic phase based on an ethyl ester copolymer of PVM/MA, ethanol and dimethicone, an aqueous phase based on PVP/PA copolymer and an oily phase comprising oleth-20, cocamide MEA and steareth-16.
- the presence of ethanol in such a formulation makes it unsuitable especially for the treatment of radiation-induced dermatitis because it will cause tingling and burning sensation in patients with damaged skin.
- Patent document US201 10224216 is also known, which describes a method for treating erythema induced, for example, by physical procedures, such as laser radiation, UV radiation, radiofrequencies, radiotherapy, light-emitting diodes, by topical administration.
- a composition in particular in the form of a cream, comprising in particular brimonidine tartrate, PEG-300 and ⁇ PEG-6 stearate.
- a topical product for therapeutic purposes usually consists of an active ingredient and excipients.
- the choice of excipients is essential to guarantee the efficacy of the medicinal product by solubilizing the active ingredients and optimizing their skin penetration, for the stability of the galenic form and its texture, for the local tolerance e ⁇ for patient compliance.
- a complex and complementary challenge is to identify the optimal balance of these key factors to deliver a product that meets the needs of patients, healthcare professionals and regulators.
- Brimonidine is ⁇ indeed a hydrophilic molecule e ⁇ therefore has a difficult penetration through the lipid stratum corneum.
- the brimonidine is in a hydrophilic medium (epidermis, in particular the granular layer and the basal layer then the dermis), to be then eliminated, thus resulting in a loss of effectiveness in terms of vasoconstriction.
- the structure of the barrier formed by the skin therefore constitutes a real challenge for obtaining a topical formulation intended to be applied to the skin allowing the vasoconstrictor active ingredient on the one hand ⁇ to pass the outer lipid layer and then not to be rapidly eliminated at the level of the lower hydrophilic layers in order to have a rapid, constant and prolonged vasoconstrictor effect for a period of 16 hours or even 24 hours.
- the concentration of active vasoconfricfeur used must not be too high because it will then entail a risk of significant exposure and potentially harmful at the systemic level.
- compositions intended for topical application may cause side effects which may limit their use and therefore their effectiveness.
- certain active agents have the major disadvantage of inducing irritation which can lead to poor tolerance of the product. This can thus create in the patient a behavior of non-compliance with the treatment and dissatisfaction with the said treatment.
- the formulation of MIRVASO® gel based on methyl parahydroxybenzoate, propylene glycol, carbomer, phenoxyethanol, glycerol, titanium dioxide, sodium hydroxide and ⁇ purified water is ⁇ for example not suitable for the prevention of radiation-related injuries; such a formulation has non-optimal pharmacokinetics with limited activity from 6 hours to 12 hours after application.
- it contains particles of titanium dioxide which interfere with the radiation if the latter is used for therapeutic purposes such as in the prevention or treatment of radiation dermatitis.
- Radiation dermatitis are ⁇ lesions that can be painful, are ⁇ worrying for the patient and ⁇ can lead to temporary or permanent discontinuation of treatment.
- emollients applied a few hours after the radiation session (for example DEXERYL®, TOPICREME®) moisturize the skin and bring transitory well-being to the patient.
- radiodermatitis lesions such as creams based on hyaluronic acid, TETA® cream or BIAFINE®. It is nevertheless recalled here that these treatments have not been proven to be effective and that, on the contrary, clinical studies have concluded that there is no effect.
- Topical corticosteroids for example DIPROSONE®
- DIPROSONE® Local topical corticosteroids
- the theoretical principle of use of these products is ⁇ to reduce the inflammation caused by radiotherapy. If topical corticosteroids do not bring ⁇ real benefits on development of radiodermatitis, they are effective in the event of a local allergic reaction (for example in the event of eczema linked to the adhesives used for markings).
- a problem which the present invention proposes to solve consists in developing an optimized topical formulation based on a well-established vasoconstrictor, such as brimonidine tartrate, aimed at improving the duration and potency of the vasoconstrictor to prevent and ⁇ significantly reduce the main cutaneous side effects caused by radiation, particularly in the treatment of cancer by radiotherapy.
- a vasoconstrictor such as brimonidine tartrate
- the Applicant has developed a new topical composition which improves the duration and potency of vasoconstriction by allowing bioavailability of the vasoconstrictor in the dermis and epidermis for a period greater than 12-14 hours, to provide protection of the skin against skin damage induced by radiation and ⁇ more particularly against the cutaneous side effects of radiotherapy treatment while avoiding any interference with the radiotherapy rays which would reduce ⁇ their effectiveness on the treated tumor or the radiation field.
- hydrophilic compounds distribute more freely in viable tissues and are cleared by circulation from the underlying local vasculature.
- an optimal and complex compositional balance must be identified to modulate variables such as thermodynamics, residual surface solubility, solubility in the stratum corneum and penetration and persistence in viable tissues (solvent pull/drag effects).
- compositions according to the invention have been established around optimal solvent systems which facilitate cutaneous administration and provide adequate physical, chemical and microbiological stability, in addition to appropriate local tolerance and cosmetic elegance.
- the optimized topical composition thus proposed by the Applicant improves the duration of vasoconstriction (with a duration of at least 14 up to 24 hours) as well as the power thereof without disturbing the passage of radiation through the skin, which would compromise its effectiveness.
- composition according to the invention will allow the creation of a reservoir of polar vasoconstrictor active ingredient at the level of the stratum corneum, a phenomenon usually obtained only with lipophilic molecules such as corticosteroids, the polar molecules generally being "washed out” quickly by the circulation blood. This allows persistence in the skin and therefore a maximum and rapid effect during each re-application. These kinetics allow maximum preventive effectiveness and offer flexibility of use to patients and radiotherapists.
- composition adapted in particular to treatment by radiotherapy makes it possible to promote patient compliance and to maximize the effectiveness of the anti-cancer treatment.
- the new topical formulation thus developed by the Applicant is well tolerated since it is non-irritating or very slightly irritating compared to the compositions of the prior art, with improved skin penetration and solubilization of brimonidine tartrate.
- compositions according to the invention developed are also economical, easy and quick to prepare.
- compositions in a form suitable for topical administration on a water basis comprising a vasoconstructor, said composition being in the form of an emulsion, preferably water in oil or oil in water, more preferably oil in water, comprising liquid crystals and said vasoconstructor being chosen from brimonidine or its salts, in a solvanized phase comprising:
- hydrophilic film-forming agent chosen from a Polyvinylpyrrolidone/Vinyl Acefafe copolymer, polyvinylpyrrolidone (PVP) in a non-crosslinked, cross-linked or acetate form, taken alone or in combination, preferably a Polyvinylpyrrolidone/Vinyl Acefafe copolymer as hydrophilic film-forming agent;
- PVP polyvinylpyrrolidone
- an emulsifier chosen from the association PEG-75 sfearafe and glyceryl monosfearafe and the association polyoxyefhylene-20 sorbifan monosfearafe (polysorbafe-60) and cefosfearyl alcohol;
- an oily phase suitable for obtaining an emulsion preferably water in oil or oil in water, more preferably oil in water, comprising liquid crystals.
- composition according to the invention for its use as a medicament.
- Figure 1 shows the stability measurements using the LUMiSize® for the compositions 19-0155.0045 (W/O emulsion based on Brij/Arlamol), 19-0155.0065P (W/O emulsion based on Brij/Arlamol), 19 -0155.0090 (W/O emulsion based on Gelof 64) and 19-0155.0091 (W/O emulsion based on Polawax).
- Figure 2 shows the stability measurements using the LUMiSizer® for compositions 19-0155.0044, 19-0155.0070P, 19-0155.0076/F2, 19-0155.0083, 19-0155.0086, 19-0155.0088 and 19-0155.0089.
- Figure 3 represents the viscosity measurements obtained with different compositions using the reference composition 19-0155-0090P/F3 according to the process conditions carried out within the framework of example 5 and more particularly of Table 14.
- Figure 4 represents the skin whitening scores obtained with different W/O emulsion compositions 19.0155-0083/Fl (based on Gelof-64), 19.0155-0087/Fl (based on Gelof-64) and 19.0155.0086A /F 1 (based on Polawax).
- Figure 5 represents the skin whitening scores obtained with different emulsion compositions 19-0155.0091 / Fl (based on Polawax), 19-0155.0089 / Fl (based on Brij) and 19-0155-0090 / Fl (based on of Gelof).
- FIG. 6 represents the skin whitening scores obtained with various active oil-in-water emulsion compositions (comprising brimonidine fartrafe) or without active agent (comprising only the vehicle).
- Figure 7 represents the skin whitening scores obtained with different active oil-in-water emulsion compositions (including brimonidine fartrafe, 19-0155-0102/F5) or without active (including only the vehicle, 19.0155-0102P/F2) .
- FIG. 8 represents the mean erythema scores obtained with various active oil-in-water emulsion compositions (comprising brimonidine fartrafe) or without active agent (comprising only the vehicle).
- Figure 9 represents the skin whitening scores obtained with reference vasoconstructing products.
- Figure 10 represents the skin whitening scores obtained with a MIRVASO composition modified with 1.5% w/w of brimonidine fartrafe (19-0155-0098/Fl), a Norepinephrine solution and MIRVASO® (0.5% w/ p of brimonidine fartrafe).
- the invention relates to a composition in a form suitable for topical water-based administration comprising a vasoconstructor.
- the topical composition according to the invention is characterized in that it is in the form of an emulsion, preferably water in oil or oil in water, more preferably oil in water, comprising liquid crystals.
- Liquid crystals are ⁇ infinite aggregates of molecules that greatly improve solubilization and ⁇ facilitate emulsification.
- Liquid crystal formulations offer several advantages as vehicles for topical compositions, including:
- the topical composition according to the invention is characterized in that it comprises a vasoconstrictor chosen from brimonidine or its salts, in a solvent phase comprising:
- hydrophilic film-forming agent chosen from a Polyvinylpyrrolidone/Vinyl Acetate copolymer (KOLLIDON VA 64®), polyvinylpyrrolidone (PVP) in a non-crosslinked, crosslinked or acetate form, taken alone or in combination, preferably a Polyvinylpyrrolidone/Vinyl Acetate copolymer as agent hydrophilic film former; - glycerin;
- an emulsifier chosen from the combination PEG-75 stearate and glyceryl monostearate and the combination polyoxyethylene-20 sorbitan monostearate (polysorbate-60) and cetostearyl alcohol;
- an oleic acid or an oleic alcohol preferably an oleic alcohol
- an oily phase suitable for obtaining an emulsion preferably water in oil or oil in water, more preferably oil in water, comprising liquid crystals.
- salts or pharmaceutically acceptable salt(s) are meant those salts of a compound of interest which are safe and effective for topical use in mammals and which possess a desired biological activity.
- Pharmaceutically acceptable salts include salts of acidic or basic groups present in the specified compounds.
- Pharmaceutically acceptable acid addition salts include, but are not limited to, hydrochloride, hydrobromide, hydroiodide, nitrate, sulfate, bisulfate, phosphate, acid phosphate, isonicotinate, acetate, lactate, salicylate, citrate, tartrate, pantothenate salts.
- Suitable base salts include, but are not limited to, aluminum, calcium, lithium, magnesium, potassium, sodium, zinc, and diethanolamine salts.
- hydrate means a compound of interest, or a pharmaceutically acceptable salt thereof which further comprises a stoichiometric or non-stoichiometric amount of water bound thereto by non-covalent intermolecular forces.
- the brimonidine used in the compositions according to the invention is brimonidine tartrate, although the salt form presents a challenge from a stability point of view for an emulsion, water-in-oil or oil-in-water formulation.
- the salts can interact with surfactants and nonionic polymers and reduce their aqueous solubility and thus harm the physical stability of the semi-solid formulation.
- the salt form of the active generates a relatively high aqueous solubility and advantageously allows the design and evaluation of aqueous-based formulations, which can offer improved performance in terms of sensory and local tolerance.
- Concentrations of between 0.15% and 3.00% of brimonidine or its salts, preferably brimonidine tartrate, by weight of the total weight of the composition are preferably used to obtain the effectiveness and an improved duration of the effect until 24 hours after application while preventing any risk of systemic exposure.
- the composition according to the invention comprises brimonidine or its salts, preferably brimonidine tartrate at a concentration of between 0.50% and 2.50% by weight of the total weight of the composition, preferably between 0.75 % and 1.50% w/w, plus preferably between 1.00% and 1.50% w/w, even more preferably 1.00% or 1.50% W/W
- the concentration of brimonidine, preferably of brimonidine tartrate, and the dose thus applied is advantageously adapted according to the site of application.
- the barrier formed by the skin is thicker, in particular in terms of the stratum corneum to be crossed at the level of the feet and hands than of the scalp, the rest of the body and in particular the chest, having an intermediate thickness.
- the concentration preferably used is advantageously lower on the scalp, for example of the order of 0.15-0.5% w/w, compared to that used on the rest of the body, for example the chest with a concentration of 0.75-1.5% w/w, or even that used in the feet and hands, for example 1.5-3% w/w.
- the oily phase of the water-in-oil or oil-in-water emulsion composition comprising liquid crystals according to the invention comprises cetyl alcohol and stearyl alcohol, taken alone or in combination, and/or a triglyceride ester of saturated caprylic and capric fatty acids from coconut/palm kernel and vegetable glycerol (Miglyol 812N), a Polypropylene Glycol (PPG)-l l stearyl ether (Arlamol PSI 1 E-LQ-[RB]) , taken alone or in combination.
- a triglyceride ester of saturated caprylic and capric fatty acids from coconut/palm kernel and vegetable glycerol (Miglyol 812N)
- PPG Polypropylene Glycol
- Arlamol PSI 1 E-LQ-[RB] taken alone or in combination.
- the oily phase comprises a combination of cetyl alcohol and stearyl alcohol.
- the oily phase of the water-in-oil or oil-in-water emulsion composition comprising liquid crystals according to the invention preferably comprises cetyl alcohol, stearyl alcohol and oleyl alcohol, taken in combination, at a concentration of between 1% and 15% by weight of the total weight of the composition, preferably between 2.5% and 10% w/w.
- the oily phase comprises a combination of triglyceride ester of saturated coconut/palm kernel caprylic and capric fatty acids and glycerol of plant origin and PPG-11 stearyl ether.
- the oily phase of the water-in-oil or oil-in-water emulsion composition comprising liquid crystals according to the invention preferably comprises the triglyceride ester of caprylic and capric fatty acids saturated with coconut/palm kernel and glycerol of plant and PPG-11 stearyl ether taken in combination at a concentration of between 5% and 10% by weight of the total weight of the composition.
- the topical composition according to the invention is characterized in that it comprises polyethylene glycol (PEG) in combination with propylene glycol (PG).
- PEG polyethylene glycol
- PG propylene glycol
- PEGs polyethylene glycols
- the high solubilizing capacity of PEGs can ⁇ result in suboptimal thermodynamics for topical administration, and ⁇ when used at high concentrations, product transformation, often associated with evaporation of volatile components such as water, cannot ⁇ be used to enhance dermal release.
- these features may reduce delivery efficiency, although high concentrations are possible; much of the applied dose of topical agents remains on the surface of the skin or is lost to the environment by contact transfer.
- Increased delivery efficiency, fraction of the applied dose may ⁇ limit the need to increase the dose to achieve targeted levels of dermal delivery and the need to use high concentrations of PEG.
- the PEGs are essential to the topical formulation.
- PEGs with small molecular weights up to PEG-600 are preferably used, more preferably PEG-400 and even more preferably PEG- 400 SR advantageously promoting the stability and tolerance of the water-in-oil or oil-in-water emulsion composition according to the invention by limifaning the potential for irritation, eliminating polar impurities and thus reducing excipient-active interaction (brimonidine fartrafe) and subsequent degradation of the active.
- PEG-400 or PEG-400 SR has relatively low penetration into the stratum corneum due to its molecular weight and high polarity (low partition coefficient), it is the preferred PEG used in the composition.
- emulsion, water in oil or oil in water according to the invention to reduce the rate of precipitation of the active agent at the surface of the skin e ⁇ in the upper layers of the stratum corneum, for surface solubilization. This promotes sustained delivery of brimonidine fartrafe into the viable layers of the skin and ⁇ specifically into the vasculature of the dermal plexus where the target site of brimonidine fartrafe is located.
- PEG-400 or PEG-400 SR has adequate solubility to promote better retention of brimonidine fartrafe in solution on the surface of the skin and in the upper layers of the stratum corneum.
- the composition according to the invention comprises PEG at a concentration of between 1% and 20% by weight of the total weight of the composition, preferably between 5% and 15%, more preferably of 10%.
- Propylene glycol (PG, 1,2-propanediol) is ⁇ a clear, colorless, hygroscopic liquid that is widely used as a solvent and preservative in a variety of parenteral and non-parenteral pharmaceutical formulations.
- PG is ⁇ known to be a better general solvent than glycerin e ⁇ dissolves a wide variety of materials including corticosteroids, phenols, barbiturates, vitamins (A e ⁇ D), most alkaloids e ⁇ de many local anesthetics.
- PG exhibits 50% of the solubilizing capacity of glycerin.
- PG As an antibacterial agent, PG has an effect similar to that of ethanol; however, it is ⁇ slightly less effective against mold with a profile comparable to glycerin.
- PG also exhibits some volatility: although a fraction of the applied dose evaporates upon application to the skin or at least within 37 hours after application, a much larger portion penetrates the stratum corneum. e ⁇ penetrates the deeper layers of the skin.
- the relatively rapid penetration of PG through the stratum corneum and its volatility can deplete the residual vehicle of its solvent, increase the thermodynamic activity of the active in the vehicle and thus modify the driving force of diffusion.
- penetration and permeation of PG can also disrupt the stratum corneum lipid barrier and therefore reduce diffusional resistance.
- PG thus has favorable physico-chemical properties in terms of penetration e ⁇ skin permeation e ⁇ es ⁇ absorbed through the skin. Therefore, solutes that are ⁇ easily dissolved by PG (i.e. high solvent/vehicle affinity) may advantageously benefit from enhanced skin penetration via a solvent resistance mechanism or pulling effects.
- a fortiori, PG is ⁇ known to penetrate the skin faster than most active ingredients and therefore the precipitation of the active ingredient on the surface of the skin will limit its duration of action.
- concentrations of PG are generally limited to about 20% w/w or less, to avoid local irritant reactions and cause systemic toxicity issues.
- the composition according to the invention comprises PG at a concentration of between 5% and 40% by weight of the total weight of the composition, preferably between 10% and 30%, more preferably between 15% and 25%, even more preferably 20%.
- PEG and PG are used in a ratio of 1:1 to 1:5, preferably 1:2.
- the composition according to the invention comprises polyethylene glycol (PEG) at a concentration of 10% by weight of the total weight of the composition in combination with propylene glycol (PG) at a concentration of 20% by weight of the total weight of composition.
- PEG polyethylene glycol
- PG propylene glycol
- the topical composition according to the invention is characterized in that it comprises a hydrophilic film-forming agent chosen from a polyvinylpyrrolidone/vinyl acetate copolymer, polyvinylpyrrolidone (PVP) in a non-crosslinked, crosslinked or acetate form, taken alone or in combination.
- a hydrophilic film-forming agent chosen from a polyvinylpyrrolidone/vinyl acetate copolymer, polyvinylpyrrolidone (PVP) in a non-crosslinked, crosslinked or acetate form, taken alone or in combination.
- the composition according to the invention comprises the hydrophilic film-forming agent, taken alone or in combination, at a concentration of between 0.1% and 1.5% by weight of the total weight of the composition, preferably between 0. 25% and 1.4%, more preferably between 0.5% and 1.3%, even more preferably between 0.75 and 1.25, even more preferably 1%.
- the topical composition according to the invention comprises a Polyvinylpyrrolidone/Vinyl Acetate copolymer (KOLLIDON VA 64®) as hydrophilic film-forming agent.
- a Polyvinylpyrrolidone/Vinyl Acetate copolymer (KOLLIDON VA 64®) as hydrophilic film-forming agent.
- the composition according to the invention comprises the Polyvinylpyrrolidone/Vinyl Acetate copolymer (KOLLIDON VA 64®) at a concentration of between 0.1% and 1.5% by weight of the total weight of the composition, preferably between 0. 25% and 1.4%, more preferably between 0.5% and 1.3%, more preferably still between 0.75 and 1.25, even more preferably 1%.
- KLLIDON VA 64® Polyvinylpyrrolidone/Vinyl Acetate copolymer
- the topical composition according to the invention is characterized in that it additionally comprises glycerine.
- Glycerin (glycerol) is a well-known humectant that can increase water retention in the stratum corneum and improve hydration.
- Glycerin is also known and used to support the normal functioning of the skin barrier, promote skin elasticity and plasticity, improve skin smoothness and provide anti-irritant effects. Glycerin is in fact capable of attracting water into the stratum corneum from the epidermis and the atmosphere. Due to its relatively high polarity, glycerin does not penetrate the skin to the same degree and depth as propylene glycol but can ⁇ accumulate and form a reservoir in hydrophilic regions of the stratum corneum and increase water content .
- Glycerin's interaction with the stratum corneum, its skin distribution, and its relatively high solubility for brimonidine ⁇ ar ⁇ ra ⁇ e provide benefits in terms of improving cutaneous administration e ⁇ prolonging cutaneous penetration without causing a sticky effect on the surface of the skin.
- the composition according to the invention comprises glycerin at a concentration of between 1% and 20% by weight of the total weight of the composition, preferably between 2% and 15%, more preferably between 3% and 10 %, even more preferably 4%.
- the combination of PG e ⁇ with glycerin improves the distribution of the active ingredient, preferentially brimonidine ⁇ ar ⁇ ra ⁇ e in the stratum corneum.
- the topical composition according to the invention is characterized in that it further comprises an emulsifier chosen from the combination PEG-75 stearate e ⁇ glyceryl monostearate e ⁇ the association polyoxyethylene-20 sorbitan monos ⁇ eara ⁇ e (polysorba ⁇ e -60) e ⁇ cetostearyl alcohol, preferably the combination PEG-75 stearate e ⁇ glyceryl monostearate (Gelo ⁇ 64).
- an emulsifier chosen from the combination PEG-75 stearate e ⁇ glyceryl monostearate e ⁇ the association polyoxyethylene-20 sorbitan monos ⁇ eara ⁇ e (polysorba ⁇ e -60) e ⁇ cetostearyl alcohol, preferably the combination PEG-75 stearate e ⁇ glyceryl monostearate (Gelo ⁇ 64).
- composition according to the invention, it comprises the combination PEG-75 stearate and glyceryl monostearate (Gelo ⁇ 64) which contains fatty ingredients having a melting point of between 46 and 66°C.
- the most important step after emulsification which is carried out at a temperature of around 65 ⁇ 5°C, is the cooling step.
- the decrease in temperature causes fatty ingredients to crystallize when they reach their transition temperature.
- the fatty emulsifiers/co-emulsifiers organize themselves around the oil droplets.
- the lipophilic co-emulsifier ⁇ remains mainly in the oil droplets while the hydrophilic emulsifian ⁇ and the amphiphilic fatty aliphatic alcohol ⁇ remain at the interface between the oil droplets and the continuous aqueous phase of the emulsion .
- the composition according to the invention comprises the emulsifier ⁇ for example GELOT 64® at a concentration of between 1% and 10% by weight of the total weight of the composition, preferably between 2% and 7%, more preferably between 3% e ⁇ 5%, even more preferably 3% w/w, or POLAWAX® at a concentration of between 3% e ⁇ 15% by weight of the total weight of the composition, preferably between 5% e ⁇ 12%, more preferably 10% w/w.
- the emulsifier ⁇ for example GELOT 64® at a concentration of between 1% and 10% by weight of the total weight of the composition, preferably between 2% and 7%, more preferably between 3% e ⁇ 5%, even more preferably 3% w/w, or POLAWAX® at a concentration of between 3% e ⁇ 15% by weight of the total weight of the composition, preferably between 5% e ⁇ 12%, more preferably 10% w/w.
- the topical composition according to the invention is characterized in that it also comprises an oleic acid or an oleic alcohol, preferably an oleic alcohol (KOLLICREAM OA®).
- the composition according to the invention comprises oleic acid or oleic alcohol at a concentration of between 0.1% and 7% by weight of the total weight of the composition, preferably between 1% and 5%, more preferably 2.5%.
- the topical composition according to the invention also comprises xanthan gum as gelling agent.
- the composition according to the invention comprises xanthan gum at a concentration of between 0.1% and 1.5% by weight of the total weight of the composition, preferably between 0.2% and 1%, more preferably respectively of 0.2-0.5% for xanthan gum.
- a flexible mixed film is thus advantageously formed on the surface of the skin with xanthan gum and the Polyvinylpyrrolidone/Vinyl Acetate copolymer (KOLLIDON VA 64®) in addition to the other non-volatile solvents, PG and PEG, making it possible to create a reservoir of brimonidine , preferably brimonidine tartrate, and thus slow down the precipitation of brimonidine and prolong its duration of action.
- brimonidine preferably brimonidine tartrate
- the topical composition according to the invention also comprises a natural or synthetic antioxidant, or a free radical scavenger.
- the antioxidant is preferably chosen from butylated hydroxyanisole (BHA), DL-tocopherol, butylhydroxytoluene (BHT), propaldehyde, ascorbate palmitate or glutathione, taken alone or as a mixture, advantageously as a mixture, preferably BHA and/or DL-tocopherol.
- the antioxidant is preferably used in the emulsion, water-in-oil or oil-in-water compositions according to the invention at a concentration of between 0.01% and 4.0% by weight of the total weight of the composition, more preferably between 0 1.1% and 1.0%, even more preferably 0.1%, for example BHA at 0.1% w/w and/or DL-tocopherol at 0.1% w/w.
- the topical composition according to the invention also comprises a paraben chosen from methyl paraben, propyl paraben or isopropyl paraben, taken alone or in combination.
- a paraben chosen from methyl paraben, propyl paraben or isopropyl paraben, taken alone or in combination.
- the composition according to the invention comprises the paraben taken alone or in combination at a concentration of between 0.01% and 0.5% by weight of the total weight of the composition, preferably between 0.1% and 0, 4%, more preferably 0.3%.
- the composition according to the invention further comprises phenoxyethanol, preferably at a concentration of between 0.15% and 1.5%, more preferably between 0.4% and 1.25%, even more preferably between 0. 5% and 1.1%, more preferably still 1% w/w; sodium benzoate, preferably at a concentration of between 0.05% and 0.5%, more preferably between 0.1% and 0.3%, even more preferably 0.2% w/w; phenylethyl alcohol as an alternative preservative, preferably at a concentration of between 0.1% and 1%, more preferably between 0.25% and 0.75%, even more preferably 0.5% w/w; and/or EDTA as chelating agent aiding in the preservation and stability of the composition, preferably at a concentration of 0.2% W/W ⁇
- the composition comprises phenoxyethanol, sodium benzoate, phenylethyl alcohol and EDTA taken in combination.
- a hydrophilic solvent phase with solvents that have hygroscopic, humectant and skin conditioning properties, including PG and glycerin, improves the solubility of brimonidine tartrate in the stratum corneum and increase the water content.
- antioxidants improves the stability of the active ingredient e ⁇ of the oily phase.
- oily phases used have been selected to promote the formation of the emulsion, physical stability, e ⁇ obtaining the desired microstructure e ⁇ to help the cutaneous delivery of the active while presenting performances appropriate sensory.
- the water-in-oil or oil-in-water emulsion compositions according to the invention thus make it possible to improve and ⁇ to prolong the cutaneous administration of brimonidine ⁇ ar ⁇ ra ⁇ e ⁇ to meet the needs of patients with adequate local vasoconstriction e ⁇ prolonged e ⁇ protection of the epidermis e ⁇ of the upper dermis against reactive oxygen species e ⁇ inflammatory mediators.
- compositions according to the invention are easy to apply and can be applied to potentially irritated skin.
- the topical compositions according to the invention have a pH between 3.5.0 and 6.5, preferably between 4.0 and 5.5, more preferably 4.5.
- the water-in-oil or oil-in-water emulsion compositions according to the invention have been designed to contain relatively high amounts of glycols, for example 20% PG and 10% PEG-400. Such relatively high concentrations of these components do not necessarily support stability and maintenance of the microstructure because they can disturb the interface and solubilize the emulsifiers and co-emulsifiers. Moreover, the addition of a relatively high concentration of an active salt, brimonidine tartrate presents a possibility of physical destabilization of the e ⁇ interface of the emulsion.
- Another object of the invention relates to an emulsion composition, water in oil or oil in water, preferably oil in water, according to the invention for its use as a medicament.
- the water-in-oil or oil-in-water emulsion composition according to the invention is used for the prevention and/or treatment of damage caused by radiation, whether this radiation is photons or protons and they are natural, therapeutic or accidental, including ultraviolet (UV) including UVA e ⁇ UVB which can cause sunburn, rays in the visible range, infrared radiation (IR), or even ionizing radiation such as X-rays and alpha, beta, gamma radiation or even proton beams.
- UV ultraviolet
- UVA e ⁇ UVB ultraviolet A e ⁇ UVB which can cause sunburn, rays in the visible range, infrared radiation (IR), or even ionizing radiation such as X-rays and alpha, beta, gamma radiation or even proton beams.
- the water-in-oil or oil-in-water emulsion composition according to the invention is used for the prevention and/or treatment of dermatitis resulting from treatment by radiotherapy, for example by X-rays.
- Saturated solutions were prepared by adding excess drug to various solvents and storing samples in sealed containers for 24 hours at room temperature with continuous agitation.
- DMSO appears to be an excellent solvent for brimonidine fartrafe and saturation was not reached even after the addition of 8.5% w/w of brimonidine fartrafe.
- the non-aqueous mixtures of solvents appear to have less solubilizing power than the mixtures containing water. Nevertheless, according to the results thus obtained, it appears that the non-volatile mixture containing PG/PEG-400/GLY/PVP (20:10:5:1) was able to solubilize approximately 22% of the active ingredient compared to the aqueous mixture PG/PEG400/GLY/PVP/water (20:10:5:1:40). This indicates that the non-volatile polar components of an aqueous gel might have some ability to dissolve brimonidine ⁇ ar ⁇ ra ⁇ e on the surface of the skin and in the stratum corneum into the residual formula even when the water has dried. ⁇ evaporated.
- brimonidine tartrate concentrations of 1% or 1.5% of brimonidine tartrate are ⁇ used, it is ⁇ possible that the active ingredient is ⁇ at around 30% or 50% saturation, respectively, in the aqueous solvent phase of the primary formulation before application. However, when applying the formulation to the surface of the skin, the water will evaporate relatively quickly.
- the average values are between 99.36% and 101.45% with a relative standard deviation of less than 1%.
- Solvent blends without Glucam E20 show the most favorable stability profile and glycerin appears to improve stability.
- Glucam E10 was included in the compositions at a concentration of 5%, the stability of brimonidine fartrafe improved. Bimonidine tartrate assay values tend to decrease with increasing Glucam concentration.
- the most stable mixture of solvents was obtained for M8 (30% Transcutol in water) then for Ml (DMSO 10%, Glucam E105% and Glycerin 5% in water).
- LUMiSizer® Centrifugation and a more quantitative rapid screening tool, LUMiSizer® has been used to maximize efficiency and to facilitate screening of different compositions.
- the multi-sample LUMiSize® is ⁇ ideal for characterization and optimization of dispersion stability, shelf life as well as particle-particle interactions, particle and flake compressibility, structural stability and ⁇ the elastic behavior of sediments and ⁇ gels. Demixing phenomena are ⁇ quantified in terms of clarification rate e ⁇ instability index, sedimentation e ⁇ particle buoyancy rate, residual turbidity, volume of separated phase (liquid or solid), consolidation of sediments or the dehydration.
- compositions mentioned in Tables 5-8 below were evaluated using a standardized LUMiSize® protocol: duration of 3 hours; temperature of 40°C and centrifugation at 4000 ⁇ ours/min.
- Table 5 19-0155.0045 (oil-in-water emulsion; BRU/ARLAMOL base; active)
- Table 6 19-0155.0065P (oil-in-water emulsion; Brij / Arlamol base; vehicle)
- Table 7 19-0155.0090/Fl (oil-in-water emulsion, Gelo ⁇ 64 base)
- Table 8 19-0155.0091 (oil-in-water emulsion, Polawax base)
- compositions comprising the active substance based on Gelof 64 (19-0155.0090) and based on Polawax (19-0155.0091) on the other hand and surprisingly have a physical stability similar to that of the vehicle 19-0155.0065P.
- Table 9 Compositions of Brij / Arlamol E examined using LUMisize® with associated preliminary physical stability (19-0155.CR2.0044A/F1; 19-0155.0070P/F1, 19-0155.0076/F2 e ⁇ 19-0155.0089 /F1)
- compositions based on BRIJ/ARLAMOL are beneficial observations.
- the vehicle (19-0155.0070P/F1) is more stable than the same composition comprising the active ingredient brimonidine farfrafe (19-0155.CR2.0044A/F1);
- composition 19-0155.0076/F2 being a little more stable than composition 19-0155.0076/F2 (showing exudation ⁇ after storage for 3 months at 40°C and ⁇ a slightly higher instability index).
- Table 12 Compositions tested for the evaluation of the stabilization of polymers at
- Example 5 Evaluation of the impact of the variation of different stages of the manufacturing process of an oil-in-water emulsion composition
- the vehicle formulated in Table 13 below was used to evaluate G impact of the variation of different manufacturing process steps on the composition in terms of appearance e ⁇ of stability.
- the initial characteristics of such a vehicle in terms of appearance, pH and viscosity are also described below.
- Table 13 Composition of vehicle prototypes 19-0155-0090P/F3 e ⁇ Physical parameters for composition 19-0155-0090P/F3
- Table 14 Summary of Process Variables Assessed Using Base Composition 19-0155-0090P
- the "deflocculator” process uses a deflocculating or dispersing blade while a paddle stirrer is used in the "Croda” process throughout the manufacturing process. Deflocculator process
- Equipment used beaker: 600 ml; type of agitation: deflocculating or dispersing blade
- Step 1 weighing and adding water, PG and PEG-400 to the beaker.
- Step 2 Weighing and adding the KOLLIDON to the mixture obtained in step 1. Mixing with the deflocculating or dispersing blade until homogenization.
- Step 3 Addition of xanthan gum previously dispersed in glycerine to the mixture obtained in step 2.
- Step 4 when the content of the mixture obtained in 3 is homogeneous, weigh and add methyl paraben.
- Step 5 no more than 20 minutes before emulsification, the phenoxyethanol is introduced into the mixture obtained in step 4.
- Step 6 weighing and adding all the excipients constituting the fatty phase. Heat up to 70°C and mix until homogenized.
- Stage 7 at 70°C, pour the mixture of phase B obtained in stage 6 into the mixture of phase A obtained in stage 5, mixing for 10 minutes at 500 ⁇ ours/min.
- Step 8 Remove the mixture obtained in step 7 from the heating plate, allow to cool to 35°C while stirring at 200-300 ⁇ ours/min.
- Step 9 Between 30°C and 35°C, the formulation increases in viscosity and a spatula is used to remove the product from the sides of the beaker.
- Step 10 Once the mixture obtained in step 9 is homogeneous, adjust to approximately pH 4.5 - 5 using a 10% citric acid solution.
- Step 1 1 Once the pH has been adjusted, mix using the deflocculating / dispersing blade for 20 minutes at approximately 200 ⁇ ours/min.
- Step 12 once step 1 1 is completed, complete with water (qsp).
- Step 1 weighing e ⁇ addition of water e ⁇ of methyl paraben in the beaker.
- Step 2 Weighing and adding the KOLLIDON to the mixture obtained in step 1. Mixing with the paddle stirrer until homogenization.
- Step 3 Addition of xanthan gum previously dispersed in glycerine to the mixture obtained in step 2 at 65°C.
- Step 4 weighing and adding all the excipients constituting the fatty phase. Heat up to 70°C and mix until homogenized.
- Stage 5 70°C, pour the mixture of phase B obtained in stage 4 into the mixture of phase A obtained in stage 3, mixing for 2 minutes at 1 1500 ⁇ ours/min.
- Step 6 Remove the mixture obtained in step 5 from the heating plate, allow to cool to 35°C while stirring at 200-300 ⁇ ours/min.
- Step 7 While cooling, introduce PG e ⁇ PEG-400 into the mixture obtained in step 6.
- Step 8 at 35°C - 40°C, weigh and add phenoxyethanol to the mixture obtained in step 7.
- Step 9 At about 30°C, the formulation increases in viscosity and a spatula is used to remove the product from the walls of the beaker.
- Step 10 Once the mixture obtained in step 9 is homogeneous, adjust to approximately pH 4.5 - 5 using a 10% citric acid solution.
- Step 1 1 Once the pH has been adjusted, mix using the paddle stirrer for 30 minutes at approximately 200 ovens/min.
- Step 12 once step 1 1 is completed, complete with water (qsp).
- microstructure obtained under these circumstances is the most efficient for drug delivery because the droplet and liquid crystal/lamellar gel phases are small and high density.
- Such a microstructure maximizes the specific surface of the liquid crystal/lamellar gel phases to facilitate the transfer of the active ingredient into the skin and thus improve vasoconstriction, in terms of intensity of vasoconstriction and prolonged duration of vasoconstriction.
- the size of the droplets is therefore influenced by the process used and the “Croda” process tends to reduce the size of the droplets to a greater extent than the “Defloculator” process. This is most likely due to the use of a high shear mixer during the emulsification process and the subsequent use of a paddle stirrer.
- Cooling rate was also identified as an important variable, and ambient air cooling yielded the most satisfactory results in this test ⁇ .
- the phenoxyefhanol should advantageously be introduced after the emulsification step.
- the active phase (including the active) is ⁇ introduced after emulsification, it must not be heated.
- microsfrucfure was significantly influenced by the elimination of glycols with a variation of the droplet faulting e ⁇ of the liquid crystal/lamellar gel phase faulting with the “deflocculator” and “Croda” processes.
- Microsfrucfure does not appear to be significantly affected by this minor formulation change when manufactured using the “deflocculator” process.
- Example 6 Evaluation of the Effect on Skin Whitening of Different Compositions Using an In Vivo Vasoconstriction Model
- compositions were tested in triplicate using the in vivo vasoconstriction protocol as described below. 60 microliters of each composition were applied once in a blind random manner at 8 a.m. to the upper chest, using a positive displacement pipette, on a 10 cm2 area defined using plastic O-rings.
- composition 19-0155,0086A/F 1 produced a slightly better overall profile than the Gelo ⁇ 64 based compositions ( 19-0155-0083/F 1 and ⁇ 19-0155-0087/F 1). It should be noted that composition 19-0155.0086A/F 1 also contains oleic alcohol (KOLLICREAM OA, 2.5%) and KOLLIDON VA-64, which improve and prolong twice the cutaneous administration of the locally applied asset.
- KOLLICREAM OA oleic alcohol
- KOLLIDON VA-64 which improve and prolong twice the cutaneous administration of the locally applied asset.
- composition based on Gelo ⁇ 64 does not impart any polymer or oleyl alcohol while the composition based on Gelo ⁇ 64 19-0155-0087/Fl imparts KOLLIDON VA-64 e ⁇ oleic alcohol. Both Gelo ⁇ 64-based formulations demonstrated superior physical stability compared to the Polawax-based formulation.
- Such oil-in-water emulsions have therefore demonstrated improved performance characteristics in terms of onset, intensity and duration of skin whitening.
- Example 7 Evaluation of the Effect on Skin Whitening of Different Compositions Using an In Vivo Vasoconstriction Model
- compositions and physical stability data for Gelo ⁇ 64 based emulsions and Polawax based emulsions tested are described in Tables 17 and 18 below.
- Table 17 Detailed compositions of Gelo ⁇ 64 emulsions tested using the in vivo vasoconstriction model
- Table 18 Detailed compositions of Polawax NF emulsions tested using the in vivo vasoconstriction model
- the Gelot-based compositions thus used are optimized versions of the Gelot 64 emulsion (19-0155-0090/Fl and 19.0155-0103/Fl) while the Polawax emulsions are optimized variants of the Polawax emulsion (19- 0155.0091 /Fl).
- compositions were tested in triplicate using the in vivo vasoconstriction protocol as described above.
- compositions tested based on Gelot ⁇ achieved maximum whitening performance with slightly lower performance than an emulsion based on Polawax 19-0155-0133/Fl.
- This ⁇ e formula contains exactly the same concentration of active ingredient as the other compositions tested and as the other Polawax active formula (19-0155-0132/F2). The only difference is that composition 19-0155-0133/F1 contains 1.0% w/w tocopherol while 19-0155-0132/F2 contains 0.1% w/w tocopherol.
- Gelo ⁇ 64 (19-0155-0102/F5) and Polawax (19-0155-0132/F2) emulsion formulations generated similar vasoconstriction profiles.
- the degree of vasoconstriction is ⁇ similar, approximately 1-1.5 after application e ⁇ to the maximum value after approximately 4 hours.
- Vasoconstriction intensity remained in the 3.0 range up to 14 hours after application and decreased to 1.0-1.5 after 24 hours.
- Figure 7 presents the average skin whitening profiles ⁇ standard deviation of the active formula 19-0155-0102/F5 e ⁇ of the corresponding vehicle 19-0155-0102P/F2 e ⁇ also demonstrates the excellent reproducibility of the vasoconstriction test ⁇ .
- Example 9 Evaluation of the efficacy on a model of UV-induced erythema
- Active compositions comprising brimonidine ⁇ ar ⁇ ra ⁇ e and ⁇ vehicles listed in Table 19 were evaluated using the UV-induced erythema model.
- compositions were applied using the protocol as specified below. This involves application in the evening before UV irradiation and ⁇ 2 hours before UV irradiation in three healthy volunteers.
- MED erythemal doses
- Active compositions containing 1.5% brimonidine ⁇ ar ⁇ ra ⁇ e demonstrated substantial reductions in erythema scores compared to vehicles. Additional benefits in terms of anti-erythematous effects were ⁇ observed when 1.5% w/w of brimonidine ⁇ ar ⁇ ra ⁇ e is ⁇ associated with antioxidants.
- BHA and ⁇ -tocopherol have been used as model antioxidants at concentrations of 0.1% and 1% w/w.
- Formulations containing 1% BHA or 1% ⁇ -tocopherol demonstrated the most potent anfi-eryphemia effects and effectively inhibited 2 MED.
- Formula 19-0155.0102/F5 (Gelo ⁇ 64 O/W liquid crystal emulsion) produced the greatest anti-erythema effect.
- Example 10 Performance of reference products in the skin whitening model
- the skin whitening (vasoconstriction) model was tested using reference pharmaceuticals known to induce skin whitening/vasoconstriction. Initial studies were ⁇ performed with:
- Norepinephrine hydrochloride solution (82 mg/ml in 70:30 ethanol:water) as used by Fahl (Effect of topical vasoconstrictor exposure upon tumoricidal radiotherapy. In ⁇ J Cancer: 135(4):981-988, 2014 ) e ⁇ similar to the wording used by Cleary et ⁇ al (Significan ⁇ suppression of radiation dermatitis in breas ⁇ cancer patients using a topically applied adrenergic vasoconstrictor. Radiation Oncology, 2017).
- the skin whitening model allows to differentiate the skin whitening capacity caused by several actives applied in different formulations in terms of onset, intensity and duration of skin whitening.
- the model exhibits adequate reproducibility and discriminatory performance for the formulation screening phase.
- Clobetasol Propionate Cream has been selected as a well-defined product/ac ⁇ ive that is involved in skin whitening. In fact ⁇ , the efficacy and in vivo bioequivalence of topical corticosferoids (1997 FDA guidance, h ⁇ ps://www.fda.gov/media/70931/download) is ⁇ assessed using this vasoconstriction effect ⁇ .
- MIRVASO® gel did not generate significant whitening. This was expected as it was designed for application to relatively thin and sensitive facial skin in the treatment of rosacea. These products generally do not contain high concentrations of potential skin-penetrating agents due to the skin sensitivity of rosacea patients. In addition, the skin of the face is ⁇ finer than the skin of the chest, e ⁇ thus has a lower barrier to skin penetration and ⁇ to permeation. Intensity and duration of action are insufficient to meet the desired radiation dermatitis requirements.
- Norepinephrine (noradrenaline) solution produced rapid and intermediate skin whitening 1 hour after application: however, the effect began to wear off after the 4 hour observation interval. Whitening was at 0.5 or less after 10 hours and returned to baseline only after 16 hours. While the initial effects were promising, the duration and intensity of the effect was not sufficient.
- clobetasol propionate cream exhibited a len ⁇ onset of action with a gradual increase over 2 hours to a peak whitening score of 2.0 between 14 at 4 p.m. There is a rapid reduction in whitening starting at 4 p.m. and returning to baseline at 12 a.m.
- the slower onset of action ⁇ of clobetasol bleaching can ⁇ be linked to the physico-chemical characteristics of the active ingredient, whereby its lipophilic character results in the formation of a reservoir and a more limited distribution in the viable epidermis by compared to the more hydrophilic norepinephrine. It is also important to note that the pharmacodynamic mechanisms of vasoconstriction are also different for clobetasol propionate and norepinephrine.
- a modified formula of the MIRVASO type was prepared with a high dose of 1.5% w/w of brimonidine tartrate (19-0155-0098/Fl). This ⁇ e evaluation was conducted to assess the impact of an increased dose on skin whitening in a vehicle similar to MIRVASO.
- the modified MIRVASO gel (1.5% Brimonidine tartrate 19-0155-0098/Fl) caused a substantial increase in the intensity e ⁇ of the duration of skin whitening compared to the marketed MIRVASO® gel (0.5 % Brimonidine tartrate).
- the intensity of the whitening of the skin did not persist for a prolonged period of time as desired to solve the technical problem according to the invention.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dermatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Inorganic Chemistry (AREA)
- Dispersion Chemistry (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Cosmetics (AREA)
Abstract
Description
Claims
Priority Applications (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020237031786A KR20230147155A (ko) | 2021-02-19 | 2022-02-18 | 방사선으로 인한 피부 손상의 예방 및/또는 치료에 있어서의 에멀젼 조성물 및 이의 용도 |
AU2022222303A AU2022222303A1 (en) | 2021-02-19 | 2022-02-18 | Emulsion composition and uses thereof in the prevention and/or treatment of skin damage caused by radiation |
JP2023574755A JP2024507011A (ja) | 2021-02-19 | 2022-02-18 | エマルション組成物、ならびに放射線によって引き起こされる皮膚損傷の予防および/または処置におけるその使用 |
EP22706816.0A EP4294364A2 (fr) | 2021-02-19 | 2022-02-18 | Composition emulsion et ses utilisations dans la prevention et/ou le traitement des dommages cutanes causes par les rayonnements |
CN202280015431.8A CN116887811A (zh) | 2021-02-19 | 2022-02-18 | 乳剂组合物及其在预防和/或治疗由辐射引起的皮肤损伤中的用途 |
US18/264,289 US20240100045A1 (en) | 2021-02-19 | 2022-02-18 | Emulsion composition and uses thereof in the prevention and/or treatment of skin damage caused by radiation |
CA3204646A CA3204646A1 (fr) | 2021-02-19 | 2022-02-18 | Composition emulsion et ses utilisations dans la prevention et/ou le traitement des dommages cutanes causes par les rayonnements |
ZA2023/06742A ZA202306742B (en) | 2021-02-19 | 2023-06-30 | Emulsion composition and uses thereof in the prevention and/or treatment of skin damage caused by radiation |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FRFR2101621 | 2021-02-19 | ||
FR2101621A FR3119986B1 (fr) | 2021-02-19 | 2021-02-19 | Composition émulsion eau dans huile et ses utilisations dans la prévention et/ou le traitement des dommages cutanés causés par les rayonnements |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2022175434A2 true WO2022175434A2 (fr) | 2022-08-25 |
WO2022175434A3 WO2022175434A3 (fr) | 2022-10-13 |
Family
ID=75108601
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2022/054044 WO2022175434A2 (fr) | 2021-02-19 | 2022-02-18 | Composition emulsion et ses utilisations dans la prevention et/ou le traitement des dommages cutanes causes par les rayonnements |
Country Status (10)
Country | Link |
---|---|
US (1) | US20240100045A1 (fr) |
EP (1) | EP4294364A2 (fr) |
JP (1) | JP2024507011A (fr) |
KR (1) | KR20230147155A (fr) |
CN (1) | CN116887811A (fr) |
AU (1) | AU2022222303A1 (fr) |
CA (1) | CA3204646A1 (fr) |
FR (1) | FR3119986B1 (fr) |
WO (1) | WO2022175434A2 (fr) |
ZA (1) | ZA202306742B (fr) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP4306112A1 (fr) * | 2022-07-15 | 2024-01-17 | Tarian Pharma | Nouveau regime posologique d'une composition comprenant de la brimonidine pour son utilisation dans la prevention et le traitement des dommages cutanes resultant d'un rayonnement |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20110224216A1 (en) | 2009-10-26 | 2011-09-15 | Galderma Laboratories Inc. | Methods of Treating or Preventing Acute Erythema |
WO2012075319A2 (fr) | 2010-12-03 | 2012-06-07 | Allergan, Inc. | Compositions de crème pharmaceutique et leurs procédés d'utilisation |
WO2015013709A2 (fr) | 2013-07-26 | 2015-01-29 | Galderma Research & Development | Méthode de traitement de l'épaississement de la peau |
-
2021
- 2021-02-19 FR FR2101621A patent/FR3119986B1/fr active Active
-
2022
- 2022-02-18 CN CN202280015431.8A patent/CN116887811A/zh active Pending
- 2022-02-18 JP JP2023574755A patent/JP2024507011A/ja active Pending
- 2022-02-18 US US18/264,289 patent/US20240100045A1/en active Pending
- 2022-02-18 KR KR1020237031786A patent/KR20230147155A/ko unknown
- 2022-02-18 EP EP22706816.0A patent/EP4294364A2/fr active Pending
- 2022-02-18 WO PCT/EP2022/054044 patent/WO2022175434A2/fr active Application Filing
- 2022-02-18 AU AU2022222303A patent/AU2022222303A1/en active Pending
- 2022-02-18 CA CA3204646A patent/CA3204646A1/fr active Pending
-
2023
- 2023-06-30 ZA ZA2023/06742A patent/ZA202306742B/en unknown
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20110224216A1 (en) | 2009-10-26 | 2011-09-15 | Galderma Laboratories Inc. | Methods of Treating or Preventing Acute Erythema |
WO2012075319A2 (fr) | 2010-12-03 | 2012-06-07 | Allergan, Inc. | Compositions de crème pharmaceutique et leurs procédés d'utilisation |
WO2015013709A2 (fr) | 2013-07-26 | 2015-01-29 | Galderma Research & Development | Méthode de traitement de l'épaississement de la peau |
Non-Patent Citations (3)
Title |
---|
BERGE ET AL., J. PHARM. SCI., vol. 66, 1977, pages 1 - 19 |
FAHL: "Effect of topical vasoconstrictor exposure upon tumoricidal radiotherapy", INT J CANCER, vol. 135, no. 4, 2014, pages 981 - 988 |
JAMES F. CLEARY ET AL.: "Significant suppression of radiation dermatitis in breast cancer patients using a topically applied adrenergic vasoconstrictor", RADIATION ONCOLOGY, 2017 |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP4306112A1 (fr) * | 2022-07-15 | 2024-01-17 | Tarian Pharma | Nouveau regime posologique d'une composition comprenant de la brimonidine pour son utilisation dans la prevention et le traitement des dommages cutanes resultant d'un rayonnement |
WO2024013283A1 (fr) * | 2022-07-15 | 2024-01-18 | Tarian Pharma | Nouveau regime posologique d'une composition comprenant de la brimonidine pour son utilisation dans la prevention et le traitement des dommages cutanes resultant d'un rayonnement |
Also Published As
Publication number | Publication date |
---|---|
US20240100045A1 (en) | 2024-03-28 |
FR3119986A1 (fr) | 2022-08-26 |
JP2024507011A (ja) | 2024-02-15 |
CA3204646A1 (fr) | 2022-08-25 |
AU2022222303A1 (en) | 2023-09-21 |
WO2022175434A3 (fr) | 2022-10-13 |
EP4294364A2 (fr) | 2023-12-27 |
FR3119986B1 (fr) | 2024-02-16 |
KR20230147155A (ko) | 2023-10-20 |
ZA202306742B (en) | 2024-02-28 |
CN116887811A (zh) | 2023-10-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Güng | New formulation strategies in topical antifungal therapy | |
Puglia et al. | Nanoemulsions as vehicles for topical administration of glycyrrhetic acid: characterization and in vitro and in vivo evaluation | |
EP1765356B2 (fr) | Composition sous forme de spray comprenant une association de calcitriol et de propionate de clobetasol, une phase alcoolique, au moins un silicone volatile et une phase huileuse non volatile | |
EP1758588B1 (fr) | Composition pharmaceutique comprenant un onguent oleagineux et deux principes actifs solubilises. | |
FR2659554A1 (fr) | Composition pour le traitement cosmetique et/ou pharmaceutique des couches superieures de l'epiderme par application topique sur la peau et procede de preparation correspondant. | |
CA2648950A1 (fr) | Composition comprenant au moins une phase aqueuse et au moins une phase grasse comprenant de l'ivermectine | |
CA2633040C (fr) | Composition de type emulsion inverse comprenant de l'ivermectine, et ses utilisations en cosmetique et en dermatologie | |
JP2012523408A (ja) | ジクロフェナクの安定な医薬組成物 | |
JP5816194B2 (ja) | カルシポトリオール一水和物ナノクリスタル | |
EP4294364A2 (fr) | Composition emulsion et ses utilisations dans la prevention et/ou le traitement des dommages cutanes causes par les rayonnements | |
Siddalingam et al. | Topical nano-delivery of 5-fluorouracil: Preparation and characterization of water-in-oil nanoemulsion | |
US20210275554A1 (en) | Topical compsition | |
WO2022175428A1 (fr) | Composition hydrogel et ses utilisations dans la prévention et/ou le traitement des dommages cutanés causés par les rayonnements | |
WO2013178758A1 (fr) | Compositions pharmaceutiques topiques de type émulsion h/e contenant un rétinoïde | |
EP3302421B1 (fr) | Compositions comprenant au moins un principe actif disperse et des microcapsules lipidiques | |
WO2013178744A1 (fr) | Compositions topiques de type émulsion sans émulsionnant à base de particules stabilisantes | |
WO2024013283A1 (fr) | Nouveau regime posologique d'une composition comprenant de la brimonidine pour son utilisation dans la prevention et le traitement des dommages cutanes resultant d'un rayonnement | |
Shalaby et al. | Optimization of folic acid Span 60-organogel to enhance its in vitro and in vivo photoprotection: a comparative study | |
RU2807884C2 (ru) | Композиция для местного применения | |
WO2020065085A1 (fr) | Composition pharmaceutique comprenant de la brimonidine, et ses utilisations | |
TR2022020852A2 (tr) | Propoli̇s ve dekspantenol nanoemülsi̇yonlarini i̇çeren hi̇drojel ve organojel formülasyonlari | |
WO2012114051A1 (fr) | Compositions pharmaceutiques administrables par voie cutanée et destinées au traitement local de la dermatite atopique canine | |
EP2678036A1 (fr) | Compositions pharmaceutiques à action locale administrables par application cutanée |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
ENP | Entry into the national phase |
Ref document number: 3204646 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 18264289 Country of ref document: US |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112023015127 Country of ref document: BR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 202280015431.8 Country of ref document: CN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2023574755 Country of ref document: JP |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 22706816 Country of ref document: EP Kind code of ref document: A2 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2022222303 Country of ref document: AU Ref document number: AU2022222303 Country of ref document: AU |
|
ENP | Entry into the national phase |
Ref document number: 112023015127 Country of ref document: BR Kind code of ref document: A2 Effective date: 20230727 |
|
ENP | Entry into the national phase |
Ref document number: 20237031786 Country of ref document: KR Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020237031786 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2022706816 Country of ref document: EP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2022222303 Country of ref document: AU Date of ref document: 20220218 Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2022706816 Country of ref document: EP Effective date: 20230919 |